1 |
Agarwal MB, Malhotra H, Chakrabarti P, et al (2015). Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol, 36, 3-16.
DOI
|
2 |
Briere JB (2007). Essential thrombocythemia. Orphanet J Rare Dis, 2, 3.
DOI
|
3 |
Birgegard G (2015). Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol, 6, 142-56.
DOI
|
4 |
Cervantes F (2011). Management of essential thrombocythemia. Hematol Am Soc Hematol Educ Program, 2011, 215-21.
DOI
|
5 |
Carneskog J, Wadenvik H, Fjalling M, Kutti J (1996). Assessment of spleen size using gamma camera scintigraphy in newly diagnosed patients with essential thrombocythaemia and polycythaemia vera. Eur J Haematol, 56, 158-62.
|
6 |
Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al (2015). Clinical manifestations and risk factors for complications of philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev, 16, 5013-8.
DOI
|
7 |
Fabris F, Randi ML (2009). Essential thrombocythemia: past and present. Intern Emerg Med, 4, 381-8.
DOI
|
8 |
Gangat N, Wolanskyj AP, McClure RF, et al (2007). Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia, 21, 270-6.
DOI
|
9 |
Johansson P (2006). Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin Thromb Hemost, 32, 171-3.
DOI
|
10 |
Kiladjian JJ, Besses C, Griesshammer M, eta l (2013). Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clin Drug Investig, 33, 55-63.
DOI
|
11 |
Lan HF, Fang ZH, Zhang Y, et al (2008). Clinical analysis of 438 patients with essential thrombocythemia. Zhonghua Xue Ye Xue Za Zhi, 29, 587-91.
|
12 |
Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA (2008). Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol, 83, 359-62.
DOI
|
13 |
Posfai E, Marton I, Nemes A, Borbenyi Z (2015). Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia. Orv Hetil, 156, 558-63.
DOI
|
14 |
Sag SO, Gorukmez O, Ture M, et al (2015). MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev, 16, 443-9.
DOI
|
15 |
Sazawal S, Bajaj J, Chikkara S, et al (2010). Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Re,132, 423-7.
|
16 |
Tefferi A, Barbui T (2015). Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, riskstratification and management. Am J Hematol, 90, 162-73.
DOI
|
17 |
Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, et al (2015). The burden of JAK2V617F mutated allele in turkish patients with myeloproliferative neoplasms. J Clin Med Res, 7, 161-70.
DOI
|
18 |
Thiele J, Kvasnicka HM, Orazi A, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 48.
|
19 |
Varghese SJ, Bahey El Din M, Al Hendi M, Kumar R (2013). Essential thrombocythaemia: a single institution experience of 16 years. Indian J Hematol Blood Transfu, 29, 139-46.
DOI
|
20 |
Yang JJ, Chen H, Zheng XQ, et al (2015). Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. Asian Pac J Cancer Prev, 16, 2219-25.
DOI
|
21 |
Zhang ZR, Duan YC (2014). Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. Asian Pac J Cancer Prev, 15, 1681-4.
DOI
|